Pure Global

Phase 0/1 Study of 212Pb-NG001 in mCRPC - Trial NCT05725070

Access comprehensive clinical trial information for NCT05725070 through Pure Global AI's free database. This Phase 1 trial is sponsored by ARTBIO Inc. and is currently Not yet recruiting. The study focuses on Metastatic Castration-resistant Prostate Cancer. Target enrollment is 23 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05725070
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05725070
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Phase 0/1 Study of 212Pb-NG001 in mCRPC
Phase 0/1 Theragnostic Study in Patients With Metastatic Castration Resistant Prostate Cancer in Need of Salvage Therapy, Selected by 18F-PSMA-PET Imaging and Treated by Alpha-therapeutic Radioligand 212Pb-NG001

Study Focus

212Pb-NG001

Interventional

drug

Sponsor & Location

ARTBIO Inc.

Oslo, Norway

Timeline & Enrollment

Phase 1

Mar 01, 2023

Oct 01, 2023

23 participants

Primary Outcome

Feasibility of SPECT/CT gamma camera imaging for uptake of 212Pb-NG001

Summary

The purpose of this study is to evaluate the imaging feasibility and safety of 212Pb-NG001.

ICD-10 Classifications

Malignant neoplasm of prostate
Hyperplasia of prostate
Carcinoma in situ: Prostate
Special screening examination for neoplasm of prostate
Dysplasia of prostate

Data Source

ClinicalTrials.gov

NCT05725070

Non-Device Trial